Statin benefits on cardiovascular risk reduction appear proportional to the degree of LDL cholesterol (LDL-C) reduction. Despite prior arguments that pleiotropic effects were responsible for the greater therapeutic impact of the statin class [1] , recent trials of adjunctive therapy to statins have only further supported LDL lowering as the principle therapeutic mechanism [2, 3] . Adding these new drug classes, the most impactful of which may be the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, to statins facilitate the achievement of extremely low LDL-C levels. As cholesterol plays a crucial role in brain development, there has been growing concern regarding the adverse effects of the low LDL-C achieved by these drugs [4 & ]. Adverse neurocognitive effects have been of keen interest given the progressive increase in life expectancy worldwide and came to the forefront following the Food and Drug Administration report raising concern for statin-related 'ill-defined memory loss or impairment' in 2012 [5] .
In ]. Amgen recently reported that the EBBINGHAUS cognitive function trial (a 1900 patient subset of the FOURIER trial) found evolocumab to be noninferior to placebo for affecting cognitive function [15, 16] , though results await peer review. It is also worth noting an earlier study of patients with abetalipoproteinemia and undetectable LDL-C levels, in which neurocognitive dysfunction was not seen [17] .
The results of the aforementioned studies are encouraging, especially in light of the additive cardiovascular risk reduction that PCSK9 inhibitors likely provide. Additional long-term outcome trials and postmarket surveillance are warranted, however, to further ensure drug safety. Nonetheless, for high-risk patient populations, the beneficial effects of PCSK9 inhibition appear to clearly outweigh the potential risk of neurocognitive events. A comprehensive review that summarizes available data on neurocognitive side effects resulting from statins and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, while summarizing potential underlying mechanisms. It also reviews studies examining statin or PCSK9 inhibitor administration and cognition, with the conclusion that current published evidence is inconsistent and does not suggest a direct association 7. 
